PubMed · 1980 · 36 citations · 0 references
PharmacyPharmacokineticsPharmacologyDrug MetabolismPediatric Clinical PharmacologyPediatric EndocrinologyDrug DispositionGrowth HormoneGrowth Hormone TherapyHormone MetabolismPediatric Drug EliminationPediatric PharmacokineticsDrug Metabolism PhenotypingGrowth Hormone ActionGrowth Hormone FunctionGrowth Hormone MetabolismGrowth Hormone Replacement TherapyHormone Metabolism AlterationInfant Drug EliminationPediatric Growth Hormone Replacement
Replacement therapy for six weeks with human growth hormone (hGH) in deficient children has been shown to produce a significant lengthening of amobarbital t1/2. Studies to define the time course of this effect were carried out and indicate either no change or a minimal change after one to eight days of treatment. The increased t1/2 noted at six weeks persists for at least one year. In contrast to amobarbital, theophylline was found to exhibit a shortening of t1/2 from a mean of 7.52 +/- 4.44 (SD) to a mean of 3.38 +/- 1.23 hours in four subjects. Thus, replacement therapy with hGH results in quantitatively large but opposite changes in the elimination of these two drugs. For both substrates, however, t1/2 after hGH replacement more closely resembles values reported for normal subjects. This suggests that hGH may be a major determinant of in vivo drug elimination.